Meeting
2021 Genitourinary Cancers Symposium
Is there a role for urine cytology following BCG therapy for non-muscle-invasive bladder cancer (NMIBC)?
Authors
Sarah Prattley
University Hospital of Wales, Cardiff, United Kingdom
Sarah Prattley , Ruth Jarvis , Jon Featherstone , Krishna Narahari , Murali Varma , Owen Hughes , Howard Kynaston
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Diagnostics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 404)
DOI
10.1200/JCO.2021.39.6_suppl.404
Abstract #
404
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
First Author: Neeta DSouza
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of blue light cystoscopy use among patients with non-muscle invasive bladder cancer in an equal access setting.
First Author: Sanjay Das
Poster
2023 ASCO Genitourinary Cancers Symposium
Comparison of urine cell-free DNA with blood-based screening for detection of bladder cancer.
First Author: Tyler F. Stewart
Poster
2023 ASCO Genitourinary Cancers Symposium
Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development.
First Author: Christopher Gaffney